We spend a lot of time focusing on what our advertising says to physicians, what our reps say to physicians, and what our websites and various other channels communicate to patients.
We spend a lot of time focusing on what our advertising says to physicians, what our reps say to physicians, and what our websites and various other channels communicate to patients. All are important in the marketing of pharma brands. But there’s another critical communication channel we can’t ignore: the doctor-patient conversation.
Here’s a suggestion: Do some research with physician and patients (separately) and ask them what goes on during a typical visit. Ask how a diagnosis is delivered, how medication is explained, and what is discussed in terms of disease course or future treatment. My bet is that you’ll get two entirely different accounts.
Physicians believe they are clear, thorough, and supportive. Patients feel doctors don’t have time to answer their questions. Physicians think patients have become more demanding in terms of information. Patients think they’re not getting the information they need from their doctors. This disconnect is of growing interest as doctor-patient communication is recognized as critical to good patient outcomes. Methods to improve communication are even being studied in clinical settings.
So what’s the point? The point is that your brand is often at the center of these conversations. The moment of truth for your brand isn’t when a doctor reads your ad or tells a rep she will try it on her next patient. The moment of truth is in the exam room, between the physician and the patient. That’s when your brand is introduced, suggested, explained, and prescribed. A second moment of truth comes once that script is filled-whether or not your patient takes your brand as prescribed. Success at both of these critical points relies heavily on the doctor-patient conversation.
If you don’t know how information about your brand is being communicated from your target customer to your target patient, you’re missing a critical link in the transaction chain. Efficacy expectations may not be properly set by the physician. Patients may resist therapy because they don’t understand potential side effects. Any number of communication mishaps can prevent those scripts from being written.
The good news is that you can have an impact on this conversation. But it goes beyond printing the standard “You and Your New Drug” patient brochure. It takes:
But before you try any of these, you need to first listen to what’s being said. What you hear may surprise you.
Abby Mansfield is SVP, creative director, at Topin & Associates. She can be reached at amansfield@topin.com.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.